Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Gallo, Ciro ^a   De Maio, Ermelinda ^b   Di Maio, Massimo ^b   Signoriello, Giuseppe ^a   Daniele, Bruno ^c   Pignata, Sandro ^d   Annunziata, Annalisa ^a   Perrone, Francesco ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c G RUMMO HOSPITAL   (Italy)

^d National Cancer Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33748192505     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-196     Document Type: Article

References (14)

1. Cancer of the Liver Italian Program (CLIP) Group: Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998, 352:17-20.
2. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Also KC: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002, 36(5):1221-6.
3. Perrone F, Gallo C, Daniele B, Gaeta GB, Isso F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, De Sio I, Castiglione F, Russo M, Persico M, Felder M, Manghisi OG, De Maio E, Di Maio M, Pignata S: Tamoxifen in the treatment of hepatocellular carcinoma: 5 year results of the CLIP-1 multicentre randomised controlled trial. Current Pharmaceutical Design 2002, 8(11):1013-9.
4. Nowak A, Findlay M, Culjak G, Stockler M: Tamoxifen for hepatocellular carcinoma (Cochrane Review). In The Cochrane Library Issue 1 Oxford: Update Software; 2006.
5. Nowak A, Stockler MR, Chow PKH, Findlay M: Use of tamoxifen in advanced-stage hepatocellular carcinoma: a systematic review. Cancer 2005, 103(7):1408-14.
6. Beaugrand M, N'kontchou G, Seror O, Ganne N, Trinchet JC: Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):201-11.
7. Llovet JM: Updated treatment approach to hepatocelluar carcinoma. J Gastroenterol 2005, 40(3):225-35.
8. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004, 5(7):409-18.
9. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B: Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002, 35:S109-14.
10. Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L: Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005, 23(19):4338-4346.
11. Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998, 28:751-755.
12. Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-845.
13. Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000, 355:1064-69.
14. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positive and false-negatives. Health Technology Assessment 2001, 5(33):.